13th Euro Abstracts 93.7% in age group 1 (0 ≤ 12 years) to 83.3% in age group 5 (older than 65 years). In general the lowest average refi ll-based adherence rates were obtained with medicine items containing phenobarbitone and vitamin B1 (52.0% ± 37.8); phenobarbitone (63.5% ± 47.2); primidone metabolites (69.7% ± 47.2%); clonazepam (77.8% ± 184.8) and carbamazepine (80.9% ± 151.1) CONCLUSIONS: Most of the anti-epileptic drugs had unacceptable low refi ll-adherence rates. Refi ll-adherence rates of anti-epileptic drugs decreased with an increase in the age of patients.
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COMPARISON OF ANALYIC HIERARCHY PROCESS AND CONJOINT ANALYSIS METHODS IN ASSESSING TREATMENT ALTERNATIVES IN STROKE REHABILITATION
Ijzerman M 1 , Bridges JF 2 , Van Til J 1 1 University of Twente, Enschede, The Netherlands; 2 Johns Hopkins University, Baltimore, MD, USA OBJECTIVES: There has been increasing interest novel HTA methods that will incorporate patient preferences in a more transparent and scientifi cally valid way. The fundamental problem of the assessment of benefi ts in HTA is the identifi cation, ranking and valuation of multiple health care outcomes. We used two multi-criteria methods to rank and value fi ve different treatments in stroke rehabilitation. Analytic Hierarchy Process (AHP) stems from operations research and is increasingly being used in health care to weigh patient-reported endpoints. Conjoint analysis (CA) is a stated preference method that often takes the discrete choice format. In CA, hypothetical scenarios are used to generate part-worth utilities for attributes. METHODS: To determine the clinical decision context and related criteria, a paper-and-pencil questionnaire was conducted among a sample of Dutch physiatrists united in a stroke interest group. From the lists of criteria (e.g. clinical benefi t, impact of treatment) an expert panel defi ned the AHP decision structure as well as the conjoint analysis survey format. Finally, the complete questionnaire including the AHP and CA survey was sent out to 184 patients with ankle-foot impairments. Eventually, 89 patients completed both surveys. RESULTS: On average, the prediction of preferred treatment on a group level is similar for both AHP and CA. However. on an inidividual level there seems to be more variation in treatment preference. Using AHP weights, a vast majority preferred soft-tissue surgery where most patients preferred orthopedic shoes if CA weights were used. This may have been caused by labelling effects of the attributes. CONCLUSIONS: Both methods have there pros and cons in ranking and valuing patient-reported endpoints. Of the methods AHP is relatively easy to apply. In prediction of overall outcome, both methods perform equally. However, for individual treatment preference we observed some differences. It may be concluded that the decision structure, framing and labelling of the treatment attributes are more important than the specifi c elicitation method used.
PND36 HEALTH STATUS COMPARISON BETWEEN STABLE PARKINSON'S DISEASE PATIENTS AND THOSE EXPERIENCING OFF-TIME
Buck PO 1 , White RE 1 , Castelli-Haley J 1 , Rendas-Baum R 2 , White MK 2 1 Teva Neuroscience, Kansas City, MO, USA; 2 QualityMetric Incorporated, Lincoln, RI, USA OBJECTIVES: End-of-dose wearing-off is commonly experienced by Parkinson's disease (PD) patients who have used dopaminergic therapy for several years. Although investigations of wearing-off have traditionally focused on motor fl uctuations, it is increasingly recognized that non-motor symptoms also vary between periods of "ON" (when PD symptoms are minimized due to medication) and "OFF" (when PD symptoms return). This study characterizes the self-reported health status of PD patients who experienced OFF-time as compared to those who were stable. METHODS: Recruited from an online panel maintained by Knowledge Networks, adults with self-reported doctor-confi rmed PD were screened, consented, and completed a crosssectional survey. Frequency of OFF-time was measured using the Unifi ed Parkinson's Disease Rating Scale Part IV. Demographics, PD-specifi c characteristics, the 9-item Wearing-off Questionnaire (WOQ-9), the Short Form-12v2 (SF-12), and the Parkinson's Disease Questionnaire-8 (PDQ-8) were also assessed. RESULTS: Data were available for 165 PD patients (mean age = 66.6 years; 52.7% male; mean time from diagnosis = 7.1 years). Twenty-fi ve (15%) of the patients reported experiencing no OFF-time on a typical day and were classifi ed as stable; the remaining 85% reported experiencing OFF-time. There were few signifi cant differences between the two groups in terms of demographics and PD history. Compared to those experiencing OFF-time, stable patients reported fewer motor and non-motor wearing-off symptoms based on the WOQ-9 (P < 0.05), as well as better health on the Physical and Mental Component Summary scores of the SF-12 (P < 0.05) and the Summary Index score of the PDQ-8 (P < 0.01). CONCLUSIONS: PD patients who experienced at least some OFF-time on a typical day reported worse overall physical and mental well-being than stable patients. Furthermore, both motor and non-motor wearing-off symptoms differed between the two patient groups. Additional research to understand the consequences of OFF-time would be useful, especially as it pertains to non-motor symptoms.
PND37 PATIENT AND PHYSICIAN GLOBAL PERCEPTION OF LEVODOPA/ CARBIDOPA/ENTACAPONE VS. LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING EARLY WEARING-OFF
Novartis Farmacéutica S.A., Barcelona, Spain; 2 Hospital Clínic de Barcelona, Barcelona, Spain OBJECTIVES: To compare patients' and physicians' global perceptions of Parkinson's disease (PD) in two treatment groups: levodopa/carbidopa/entacapone (LCE) vs. levodopa/carbidopa (LC). METHODS: Multicentre, double-blind, randomised phase IV study. Ninety-fi ve PD patients with early wearing-off (WO) and deterioration of activities of daily living (ADLs) were randomised to receive LCE (n = 46) or LC (n = 49) with a 3-month follow-up. Patient and physician global perception of PD was assessed at the end of the study. The PDQ-39 quality of life (QoL) questionnaire, and the longitudinal course of PD using the different parts of UPDRS (part I, part II, part III, and IV) were evaluated along the study. Differences between health improvement by patient and physician were analyzed by the Mann Whitney U-test. The mean differences from baseline to fi nal visit in PDQ-39 and in UPDRS (part I, II, IIII IV) score were analyzed by an ANCOVA model. RESULTS: Mean (SD) age was 66.4 ± 8.6 years and 50.0% were women. Half percent of patients showed stage II according to the Hoehn and Yahr classifi cation. Patient global perception showed a signifi cant better score in the LCE than in LC group (−0.9 ± 1.0 LCE and −0.4 ± 1.17 LC, p = 0. 0291). Similar results were obtained by the physician (−0.3 ± 0.8 vs. −0.4, p = 0. 0017). The adjusted mean differences in the PDQ-39 showed a trend for a higher improvement in QoL in the LCE group (6.3 ± 20.4 vs. 0.81 ± 15.6), although did not reach statistical signifi cance. The UPDRS evaluation showed a signifi cant higher 13th Euro Abstracts A395 response in part II and III (p = 0.0078 and p = 0.0072, respectively). a trend to better results for the LCE group was observed in part I and IV. CONCLUSIONS: Levodopa/ carbidopa/entacapone shows a signifi cant better patient and physician global perception in the LCE treatment group vs. LC group in PD patients with early WO and ADLs deterioration.
PND38 DIFFICULTIES IN IDENTIFYING THE ORIGINAL SOURCE QUESTIONNAIRE FOR USE IN TRANSLATIONS: THE ADAS-COG CASE STUDY
Anfray C 1 , Giroudet C 1 , Berne C 2 , Acquadro C 2 1 MAPI Institute, Lyon, France; 2 MAPI Research Trust, Lyon, France OBJECTIVES: Since its development in the 80's, variations of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), a Clinician-Reported Outcome (ClinRO) measure, have been used to monitor disease progression and treatment effi cacy in Alzheimer's disease. The objective of this study was to identify all versions used as a basis for translation in Mapi Institute projects and to take stock of existing translations. METHODS: The review was based on all ADAS-Cog translation projects performed by Mapi Institute. RESULTS: Sixteen projects were identifi ed representing a total of 70 languages and 219 translations. Translations were based on 11 source versions which differed in terms of content (number of items, order of items and instructions), and format. The number of items ranged from 11 to 15. Four studies used 13 items, but only in two cases the same items were used although in a different order. Four studies used 12 items: only two studies used the same items (with a different list of words for the Word Recognition Task), but again in a different order. Format and instructions differed in all cases. In most projects the source version provided by the sponsor was a single document mixing instructions with the rater and response forms. Only in 3 cases the original consisted in a separate instruction manual and response forms. With regard to available translations, more than one translation was identifi ed in 56 of the 70 available languages and in one language (Swedish) as many as 7 translations. CONCLUSIONS: The abundance of different versions of the same questionnaire both in its original US English form as in translations makes comparisons between studies or pooling of data diffi cult for both researchers and users. In the light of FDA's recent PRO guidance it would be benefi cial to demand the same scientifi c rigor when using ClinROs in international studies. (QoL) is an important measure that is often overlooked in the assessment of multiple sclerosis (MS). The MS International QoL (MusiQoL) questionnaire is a validated, MS-specifi c instrument. This study aimed to assess the responsiveness of the MusiQoL questionnaire to changes in Expanded Disability Status Scale (EDSS) scores in patients with MS. METHODS: In this ongoing, 24-month, multicentre, observational study, MusiQoL and EDSS scores were recorded at baseline (BL) and at 6-month intervals. The primary endpoint is change in MusiQoL index score from BL to month 24 (including effect size). Secondary endpoints include change in MusiQoL index score from BL to month 12 and change in MusiQoL scale scores. RESULTS: Of 600 patients enrolled, 474 had evaluable BL and month-12 EDSS and MusiQoL index data. At BL, mean (SD) EDSS score was 2.9 (1.9); mean (SD) MusiQoL index score was 68.5 (14.4); and mean (SD) MusiQoL scale scores ranged from 59.9 (24.8) to 85.4 (18.5). At month 12, 68 patients (14.3%) had a worse EDSS score than that recorded at BL. Mean (SD) change in MusiQoL index score was 0.48 (10.99) overall, and −1.00 (9.88) in "worsened" patients; effect sizes were 0.03 and −0.08, respectively. Changes from BL to month 12 in MusiQoL scale scores were mostly small. However, there were larger (mean [SD]) decreases in some subscales at month 12 for "worsened" patients: "Activities-of-daily-living" (−4.20 [18.07] ); "Relationship-with-family" (−5.14 [23.43] ); ); and 'Relationship-with-health care-system' (−3.56 [14.11] ). Effect sizes were −0.17, −0.25, −0.14 and −0.21 respectively. Conversely, the mean (SD) change in 'Symptoms' score was 5.36 (17.27) at month 12 for 'worsened' patients (effect size: 0.24). CON-CLUSIONS: As expected, most MusiQoL scores decreased over 12 months in patients with worsening EDSS scores, indicating poorer QoL and confi rming the utility of the MS-specifi c MusiQoL in rating QoL.
PND39 RESPONSIVENESS OF THE MULTIPLE SCLEROSIS INTERNATIONAL QUALITY OF LIFE QUESTIONNAIRE TO EXPANDED DISABILITY STATUS SCALE SCORE CHANGES IN PATIENTS WITH MULTIPLE SCLEROSIS: MONTH 12 RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY
PND40 QUALITY OF LIFE OF CAREGIVERS IN HUNTINGTON'S DISEASE-FIRST RESULTS FROM EURO-HDB STUDY
Dorey J 1 , Clay E 1 , Aubeeluck A 2 , Verny C 3 , Aballea S 1 , Squitieri F 4 , Toumi M 5 1 Creativ Ceutical, Paris, France; 2 University of Nottingham, Derby, UK; 3 Neurology Unit CHU, Angers, France; 4 Neurogenetics and Rare Disease Centre, Pozzi, Italy; 5 University Claude Bernard Lyon 1, Lyon, France OBJECTIVES: Huntington's disease (HD) is a rare neurodegenerative disease leading to sustained disability for patients and poor quality of life (QoL) for patients as well as caregivers. This study investigated the impact of HD on caregivers' QoL and its drivers. METHODS: The European HD burden study (Euro-HDB) is an ongoing cross-sectional survey among HR patients and their caregivers in six countries (France, Italy, Germany, UK, Sweden and Spain). The Huntington's disease Quality of Life Battery for Carers (HDQoL-C) short-version, a previously validated questionnaire by Aubeeluck A. and Buchanan H., was administered. Pearson correlations with generic HR-QOL (SF36, EQ5D) and the specifi c HR-QOL in HD for patients (HQOLI) were evaluated. The determinants of caregiver QOL among drivers among patients' clinical characteristics (voluntary movement disorders, chorea, depression/anxiety, psychotic disorder, cognition, temper) were studied by regression analysis adjusting on age, sex and occupational categories. The relationship between QOL of patients and caregivers were also explored. RESULTS: To date, 201 caregivers in France and 124 in Italy have been enrolled. For France (respectively Italy) 6% (12%) were completely unsatisfi ed by their overall QOL and 7% (5%) were totally satisfi ed. HDQoL-C scores were poorly correlated with generic caregiver HR-QOL: correlation equaled 0.31 for EQ5D utility and varied between 0.04 and 0.45 for the eight domains of SF36. Correlation was quite high (0.59; P < 0.01) between HDQoL-C and HQOLI. Drivers of caregiver's QoL were voluntary movement disorders (p = 0.049), depression/anxiety (p = 0.02), psychotic disorder (p = 0.01) and cognition (p = 0.01). Temper and chorea were not drivers of caregivers' QOL independently of other clinical characteristics. CONCLU-SIONS: Caregivers QOL worsens as the patient clinical characteristics deteriorate especially voluntary movement disorders, depression/anxiety, psychotic disorders and cognition disorders. Patients and caregiver QoL was indirectly correlated via patient clinical scores. The potential impact on caregiver QOL should be considered in evaluations of innovative HD treatments.
PND41 THE IMPACT OF PAIN SEVERITY AND FREQUENCY ON HRQOL IN THE BIG 5 EUROPEAN UNION COUNTRIES
Langley PC 1 , Liedgens H 2 1 University of Minnesota, Minneapolis, MN, USA; 2 Gruenenthal GmbH, Aachen, Germany OBJECTIVES: This study assesses, for an estimated EU pain population of 50 million patients, the impact of pain severity and frequency on three dimensions of health related quality of life (HRQoL): the SF-12 MCS and PCS scores and (ii) the SF-6D absolute utility scores. METHODS: The study is based on data from the internet based 2008 National Health and Wellness Survey undertaken in the UK, France, Spain, Germany and Italy. This study identifi ed 11,000 respondents (1 in 5 of the estimated big 5 EU countries) who had experienced pain in the last month. The assessment of the quantitative impact of pain status on HRQoL is estimated via three single equation generalized linear (ordinary least squares) models which estimate the impact of pain on PCS, MCS and utility scores. The model includes a range of variables which have been shown in previous population studies to impact HRQoL. These include: sociodemographic factors, health risk behaviors, comorbidity status, medication utilization, duration of medication utilization and satisfaction with care. The experience of pain is captured by a combination of severity and frequency categorical variables. RESULTS: Pain has a substantial impact on all three of the dimensions of HRQoL considered here. Compared to the reference category (mild pain experienced weekly or less) the presence of severe, daily pain has a substantial impact on SF-12 PCS scores (−13.85 points); SF-12 MCS scores (−4.72); and SF-6D utilities (−0.147). There is a marked gradient on scores by severity and frequency of pain experience. The impact of pain on HRQoL is more signifi cant than the impact of socio-demographic characteristics, health risk factors, comorbidities and the experience of pain medication. CONCLUSIONS: The presence of moderate and severe pain imposes a signifi cant burden on persons reporting pain in the big 5 EU countries; the burden increases the greater the frequency and severity.
